Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

78.65
-1.3800-1.72%
Post-market: 78.650.00000.00%19:30 EDT
Volume:882.04K
Turnover:69.21M
Market Cap:3.02B
PE:-11.99
High:80.53
Open:79.19
Low:77.50
Close:80.03
52wk High:99.50
52wk Low:40.00
Shares:38.39M
Float Shares:32.95M
Volume Ratio:2.03
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5619
EPS(LYR):-6.0116
ROE:-39.08%
ROA:-23.96%
PB:4.69
PE(LYR):-13.08

Loading ...

Disc Medicine says DISC-0974 posts durable anemia responses in Phase 2 RALLY-MF trial in myelofibrosis

Reuters
·
Jun 12

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 12

H.C. Wainwright Remains a Buy on Disc Medicine (IRON)

TIPRANKS
·
Jun 11

Disc Medicine Price Target Maintained With a $88.00/Share by Wedbush

Dow Jones
·
Jun 10

Disc Medicine (IRON) Is Down 8.6% After Mixed Trial Success And FDA Setback What's Changed

Simply Wall St.
·
Jun 10

Disc Medicine Buy Rating Reiterated as APOLLO Phase III Progress and Bitopertin Outlook Support Unchanged $100 Price Target

TIPRANKS
·
Jun 09

Disc Medicine - Expects Crl Response Submission by End of 2026

THOMSON REUTERS
·
Jun 09

Disc Medicine - Apollo Study Data Expected Q4 2026; FDA Decision Expected by Mid-2027

THOMSON REUTERS
·
Jun 09

Disc Medicine - FDA Agrees Phase 3 Apollo Study Can Support Crl Response and Potential Approval

THOMSON REUTERS
·
Jun 09

Disc Medicine Provides Update From FDA Type a Meeting for Bitopertin in Erythropoietic Protoporphyria

THOMSON REUTERS
·
Jun 09

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

GlobeNewswire
·
Jun 09

Assessing Disc Medicine (IRON) Valuation After New Trial Data And Expanded Access Program News

Simply Wall St.
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)

TIPRANKS
·
Jun 05

Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Celcuity (CELC)

TIPRANKS
·
Jun 03

Why Disc Medicine (IRON) Is Up 7.7% After Advancing Key Late-Stage Anemia Candidates

Simply Wall St.
·
Jun 03

Disc Medicine Presents Updated Positive Data From Rally-Mf Phase 2 Trial in Patients With Myelofibrosis (Mf) and Anemia at the 2026 American Society of Clinical Oncology (Asco) Annual Meeting

THOMSON REUTERS
·
Jun 02

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Jun 02

Press Release: LABRADOR IRON ORE ROYALTY CORPORATION - CHANGES TO THE BOARD OF DIRECTORS AND COMMITTEE LEADERSHIP

Dow Jones
·
Jun 02

Disc Medicine - Bitopertin Phase 3 Apollo Trial Topline Data Expected in Q4 2026

THOMSON REUTERS
·
Jun 01